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Abstract Cancer is the leading cause of death worldwide.
Nanomaterials and nanotechnologies could provide poten-
tial solutions. In this research, a novel biodegradable
poly(lactide-co-glycolide)-d-a-tocopheryl polyethylene gly-
col 1000 succinate (PLGA-TPGS) random copolymer was
synthesized from lactide, glycolide and d-a-tocopheryl
polyethyleneglycol1000succinate(TPGS)byring-opening
polymerization using stannous octoate as catalyst. The
obtained random copolymers were characterized by
1H
NMR, FTIR, GPC and TGA. The docetaxel-loaded nano-
particles made of PLGA-TPGS copolymer were prepared
by a modiﬁed solvent extraction/evaporation method. The
nanoparticles were then characterized by various state-
of-the-art techniques. The results revealed that the size of
PLGA-TPGS nanoparticles was around 250 nm. The doce-
taxel-loaded PLGA-TPGS nanoparticles could achieve
much faster drug release in comparison with PLGA nano-
particles.Invitrocellularuptakesofsuchnanoparticleswere
investigated by CLSM, demonstrating the ﬂuorescence
PLGA-TPGS nanoparticles could be internalized by human
cervix carcinoma cells (HeLa). The results also indicated
that PLGA-TPGS-based nanoparticles were biocompatible,
and the docetaxel-loaded PLGA-TPGS nanoparticles had
signiﬁcant cytotoxicity against Hela cells. The cytotoxicity
against HeLa cells for PLGA-TPGS nanoparticles was in
time- and concentration-dependent manner. In conclusion,
PLGA-TPGS random copolymer could be acted as a novel
and promising biocompatible polymeric matrix material
applicable to nanoparticle-based drug delivery system for
cancer chemotherapy.
Keywords PLGA-TPGS  Random copolymer 
Docetaxel  Nanoparticle  HeLa  Cancer chemotherapy
Introduction
Cancer is the leading cause of death worldwide [1]. Nano-
technology has the potential to have a revolutionary impact
on cancer diagnosis and therapy. Drug delivery via nano-
particles presents novel therapeutic opportunities for drugs
thatwere previouslyunsuitedtotraditional oralorinjectable
drug formulations, allowing drugs to be delivered efﬁca-
ciously while minimizing side effects and leading to better
patient compliance. Speciﬁcally, nanoparticle-based drug
delivery systems have enormous potential in addressing the
failures of traditional drugs that could not be effectively
formulated due to factors such as poor water solubility or a
lack of target speciﬁcity [1–3]. Synthetic biodegradable
polymers have been widely utilized as the polymeric matrix
materials of drug delivery systems. A few synthetic
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(e-caprolactone) (PCL), polylactides (PLA) and poly(lac-
tide-co-glycolide) (PLGA), which have been approved by
FDA, are of great interest for medical applications [4].
Among them, PLGA is one of the most widely used biode-
gradablepolymerstomakenanoparticlesforcontrolleddrug
delivery systems [4, 5]. However, these polymers were
originally synthesized to be used as surgical sutures, which
therefore have disadvantages to be used for drug delivery
systems such as too high hydrophobicity and too slow deg-
radation [6]. In addition, long-term incompatibility with
blood cells and uptake by the reticuloendothelial system
(RES) of PLGA nanoparticles as drug carrier are also a
problem [5]. One of the limiting factors in this ﬁeld is their
thrombogenic property. Thus, the surface modiﬁcation of
the nanoparticles with a blood compatible material is
important in order to improve the potential of intravenously
administered nanoparticles in the drug delivery systems. It
has been demonstrated that methoxy poly(ethylene glycol)
(mPEG)-modiﬁed nanoparticles provides protection against
interaction with the blood components, which induce
removal of the foreign particles from the blood [7].
D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS)
is a water-soluble PEG derivative of natural-source vitamin
E, which has amphiphilic structure comprising of hydro-
philicpolarheadgroup(tocopherolsuccinate)andlipophilic
alkyltail (polyethylene glycol, PEG).Its bulky structure and
large surface area make it become an excellent solubilizer,
emulsiﬁer, bioavailability enhancer of hydrophobic drugs
[6, 8, 9]. Furthermore, TPGS could improve drug perme-
ability through cell membranes by inhibiting P-glycoprotein
(permeability glycoprotein, abbreviated as P-gp), thus
enhancing absorption of drugs and reducing P-gp–mediated
multi-drug resistance in tumor cells [10–13]. It was also
found that TPGS could effectively inhibit the growth of
human lung carcinoma cells from in vitro cell culture and
implanted in vivo [14]. The superior anticancer efﬁcacy of
TPGS is associated with its increasing ability to induce
apoptosis and not due to its increased cell uptake into cells
[14–16]. Synergistic effects could be obtained by the use of
combinations of vitamin E derivatives in the presence of
other anticancer agents [15]. Random copolymerization is
known to provide new materials with properties intermedi-
ate between those of the parent homopolymers [4]. This is a
valuable method to ﬁne-tune properties to the desired
parameters. Therefore, in the present study, we synthesized
a novel biodegradable poly(lactide-co-glycolide)-d-a-toc-
opheryl polyethylene glycol 1000 succinate (PLGA-TPGS)
random copolymer in order to achieve high drug encapsu-
lation efﬁciency, desired drug release proﬁles, good bio-
compatibility and improvement in drug permeability across
cancer cell membranes, resulting in high cellular uptake and
good cytotoxicity against human cervix carcinoma cells
(HeLa) usingdocetaxel as a model anticancer drug due to its
excellent therapeutic effects against a wide spectrum of
cancers and its commercial success as the best seller among
all the anticancer agents.
Materials and Methods
Materials
D,L-lactide (3,6-dimethyl-1,4-dioxane-2,5-dione, C6H8O4)
with a purity greater than 99% was purchased from Aldrich,
Milwaukee, USA. They were recrystallized at least
three times from ethyl acetate before reaction to remove
the residual impurities in the monomer. D-a-tocopheryl
polyethylene glycol 1000 succinate (TPGS, C33O5H54
(CH2CH2O)23)wasfromSigma(St.Louis,MO,USA).Stan-
nous octoate (Sn(OOCC7H15)2), glycolide (1,4-Dioxane-
2,5-dione, C4H4O4) (purity[99%) and PLGA (50:50, MW
50,000) were also purchased from Sigma (St. Louis, MO,
USA).Docetaxelpowderofpurity99.8%waspurchasedfrom
Shanghai Jinhe Bio-Technology Co. Ltd (Shanghai, China).
AcetonitrileandmethanolwerepurchasedfromEMScience
(ChromAR, HPLC grade, Mallinckrodt Baker, USA). All
other chemicals used were of the highest quality com-
mercially available. Ultrahigh pure water produced by Boon
EnvironmentalTech.IndustryCo.,Ltd.(Tianjin,China)was
utilized throughout all experiments. Human cervix carci-
noma HeLa cells were provided by American Type Culture
Collection (ATCC, Rockville, MD).
Synthesis of PLGA-TPGS Random Copolymer
PLGA-TPGS random copolymers were synthesized by
ring-opening bulk polymerization of lactide and glycolide
monomer with TPGS in the presence of stannous octoate as
catalyst. Brieﬂy, weighted amounts of glycolide, lactide,
TPGS and 0.5 wt% stannous octoate (in distilled toluene)
were added in a reaction ﬂask. The mixture was heated to
145C and allowed to react for 16 h. Synthesis was carried
out under an oxygen- and moisture-free environment. The
resulting product was dissolved in DCM and then precip-
itated in excess cold methanol to remove unreacted
monomers and TPGS. The ﬁnal product was collected by
ﬁltration and dried under high vacuum at 45C for 48 h.
Characterization of PLGA-TPGS Random Copolymer
FTIR spectrophotometer (Thermo Nicolet, Madison, WI,
USA) was used to investigate the molecular structure of
PLGA-TPGS copolymer. In brief, the samples for FTIR
analysis were prepared by grinding 99% KBr with 1%
random copolymer and then pressing the mixture into a
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123transparent tablet. The TPGS content and number-averaged
molecular weight of the copolymer were determined by
1H
NMR in CDCl3 at 300 Hz (Bruker ACF300). The weight-
averaged molecular weight and molecular weight distribu-
tion were determined by gel permeation chromatography
(Waters GPC analysis system with RI-G1362A refractive
index detector, Waters, Milford, USA) column was used.
The mobile phase was THF delivered at a ﬂow rate of 1 ml/
min. The injection volume was 50 ll sample solution (0.1%
w/v polymer in mobile phase). The calibration curve was
established by using polystyrene standard sample (molecu-
lar weights: 5.51 9 10
4, 1.39 9 10
4, 2.97 9 10
3 and 162,
respectively). Thermogravimetric analysis (TGA, TGA
2050 thermogravimetric analyzer, USA) was carried out to
investigatethe thermal properties ofthecopolymers. During
the TGA analysis, about 5–15 mg of the random copolymer
sample was heated from 30 to 600C at a rate of 10C/min.
Preparation of Docetaxel-Loaded PLGA-TPGS
Nanoparticles
The docetaxel-loaded PLGA-TPGS nanoparticles were pre-
pared by a modiﬁed solvent extraction/evaporation method
[17]. In brief, a given amount of docetaxel and 100 mg
PLGA-TPGS copolymer were dissolved in 8 ml dichloro-
methane (DCM). The formed solution was poured into
120 ml0.03%TPGSpurewatersolutionundergentlestirring.
The mixture was sonicated for 120 s at 25 W to form O/W
singleemulsion.Theemulsionwasthenevaporatedovernight
to remove DCM. The particle suspension was centrifuged at
20,000 rpm for 15 min and then washed three times to
remove the unloaded drug and surfactant. The resulted par-
ticles were resuspended in 10 ml water and freeze-dried for
2 days. In addition, the ﬂuorescent coumarin-6–loaded
nanoparticles were prepared in the same way, except 0.1%
(w/v) coumarin-6 was encapsulated instead of docetaxel.
Characterization of Drug-Loaded PLGA-TPGS
Nanoparticles
Size and Size Distribution
The particle size and size distribution of the nanoparticles
were measured by Dynamic Light Scattering (Zetasizer
Nano ZS90, Malvern Instruments LTD., Malvern, UK).
One milligram of particles was suspended in 3 ml of pure
deionized water before measurement. The measurement
was performed in triplicate.
Surface Morphology
The nanoparticles were imaged by a ﬁeld emission
scanning electron microscopy (FESEM) system at an
accelerating voltage of 5 kV. The particle surface was
coated with platinum layer before being observed.
Surface Charge
The samples were prepared by diluting the nanoparticles
suspension with pure deionized water. Zeta potential of the
nanoparticles was measured by Laser Doppler Anemome-
try (LDA; Zetasizer Nano ZS90, Malvern Instruments
LTD., Malvern, UK). The data were obtained with the
average of three measurements.
Drug Loading and Encapsulation Efﬁciency (EE)
The docetaxel entrapped in the drug-loaded PLGA-TPGS
nanoparticles was measured by HPLC (LC 1200, Agilent
Technologies, Santa Clara, CA). A reverse-phase Inertsils
C-18 column (150 9 4.6 mm, pore size 5 mm, GL science
Inc, Tokyo, Japan) was used. Brieﬂy, 5 mg nanoparticles
were dissolved in 1 ml DCM. After DCM was evaporated
in nitrogen atmosphere, the samples were extracted by 5 ml
mobile phase (50/50 (v/v) acetonitrile/water solution).
Twenty microliters of the clear solution was used for
HPLC analysis. The ﬂow rate of mobile phase was 1 ml/
min. Retention time was controlled at 15 min. The column
efﬂuent was detected at 227 nm with a UV/VIS detector.
The drug encapsulation efﬁciency was deﬁned as the ratio
between the amount of docetaxel entrapped in nanoparti-
cles and that added in the process.
Differential Scanning Calorimetry (DSC)
The physical status of docetaxel inside the drug-loaded
PLGA-TPGS nanoparticles was investigated by differential
scanning calorimetry (DSC 822e, Mettler Toledo, Grei-
fensee, Switzerland). The samples were purged with dry
nitrogen at a ﬂow rate of 20 ml/min. The temperature was
ramped at a rate of 10C/min.
In Vitro Drug Release
In brief, 15 mg drug-loaded PLGA-TPGS nanoparticles
were dispersed in 5 ml release medium (phosphate buffer
solution of pH 7.4 containing 0.1% w/v Tween 80) to form
a suspension. The suspension was transferred into a
Regenerated Cellulose Dialysis Membrane (Spectra/Por 6,
MWCO = 1000, Spectrum, Houston, TX, USA). Then, the
closed bag was put into a centrifuge tube and immersed in
15 ml release medium. The tube was put in an orbital water
bath shaking at 120 rpm at 37.0C. Ten milliliters of
solutions was periodically removed for HPLC analysis and
replaced with fresh medium. The collected samples were
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phase. The DCM was evaporated by nitrogen stream. The
analysis procedure was the same as for the measurement of
encapsulation efﬁciency.
Cellular Uptake of Coumarin-6–Loaded PLGA-TPGS
Nanoparticles
Human cervical adenocarcinoma cancer cell lines HeLa
cells were cultured in Dubelco’s modiﬁed essential med-
ium (DMEM) supplemented with 10% fetal bovine serum
and antibiotics. The culture was maintained in incubator
containing 5% CO2 at 37C. The cells were incubated with
250 lg/ml coumarin-6–loaded nanoparticles at 37C for
4 h, rinsed with cold PBS for three times and then ﬁxed by
methanol for 10 min. Cells were stained with DAPI for
15 min and washed three with PBS. Finally, cells were
observed by confocal laser scanning microscope (CLSM,
Olympus Fluoview FV-1000, Olympus Optical. Co., Ltd.,
Tokyo, Japan). The images of the cells were determined
with differential interference contrast (DIC) channel, and
the images of coumarin-6–loaded nanoparticles and the
nuclei of the cells stained by DAPI were recorded with
following channels: blue channel (DAPI) with excitation at
340 nm and green channel (coumarin-6) with excitation at
488 nm [18, 19].
In Vitro Cytotoxicity of PLGA-TPGS Nanoparticles
HeLa cells were seeded in 96-well plates at the density
of 5,000 viable cells per well and incubated 24 h to allow
cell attachment. The cells were incubated with docetaxel-
loaded PLGA-TPGS nanoparticle suspension at 0.025,
0.25, 2.5, 10 and 25 lg/ml docetaxel concentrations and
drug-free PLGA-TPGS nanoparticle suspension with
equivalent nanoparticle concentrations of 0.25, 2.5, 25, 100
and 250 lg/ml for 24, 48 and 72 h, respectively. At the
determined time, the formulations were replaced with
DMEM containing MTT (5 mg/ml), and cells were then
incubated for additional 4 h. MTT was aspirated off, and
DMSO was added to dissolve the formazan crystals.
Absorbance was measured at 570 nm using a microplate
reader (Bio-Rad Model 680, UK). Untreated cells were
taken as control with 100% viability, and cells without the
addition of MTT were used as blank to calibrate the
spectrophotometer to zero absorbance.
Statistical Methodology
The data are expressed as mean ± SD. The signiﬁcance of
differences was assessed by Student’s t test and was con-
sidered signiﬁcant when p = 0.05.
Results and Discussions
Synthesis and Characterization of PLGA-TPGS
Random Copolymer
The PLGA-TPGS random copolymer was synthesized in
this research using the stannous octoate as catalyst. The
reaction of synthesis is schematically described in Fig. 1.
The hydroxyl end of TPGS served as initiator to selectively
cleave acyl oxygen chain of lactide or glycolide.
The FTIR spectra of the PLGA-TPGS random copoly-
mer and TPGS were showed in Fig. 2. The carbonyl band
of TPGS appears at 1,730 cm
-1. For the synthesized ran-
dom copolymer, the carbonyl band was shifted to
1,754 cm
-1. Overlapping of the CH stretching band of
PLA at 2,945 cm
-1 and that of TPGS at 2,880 cm
-1 was
observed. In the PLGA-TPGS copolymer, the CH stretch-
ing band of TPGS was decreased. The absorption band at
3,400–3,650 cm
-1 is attributed to the terminal hydroxyl
group and that at 1,045–1,500 cm
-1 is due to the C–O
stretching [20].
Figure 3 shows typical
1H NMR spectra of the PLGA-
TPGS random copolymer and TPGS monomer. The signals
at 5.2 (peak a) and 1.69 ppm (peak d) were assigned to the
–CH protons and methyl protons –CH3 of PLA segment,
respectively. The peak at 3.65 ppm (peak c) was assigned
to the –CH2 protons of PEO part of TPGS [6]. The peak at
Fig. 1 Schematic description of the synthesis of PLGA-TPGS
random copolymer
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1234.82 was assigned to the –CH2 of PGA [21]. The molecular
weight of the PLGA-TPGS random copolymer was cal-
culated using the ratio between the peak areas at 5.2 (peak
a), 4.8 (peak b) and 3.65 (peak c). The number-averaged
molecular weight of the PLGA-TPGS random copolymer
was determined to be 21,747. The ratio of glycolide, lactide
and TPGS molecular mass, which were integrated into the
PLGA-TPGS random copolymers, is 50.61, 38.95 and
10.44%, respectively.
GPC analysis further conﬁrmed that the PLGA-TPGS
random copolymer was synthesized by the ring-opening
polymerization. Figure 4 shows that the peak for TPGS
appeared at 28.23 min. Instead, the peak of the random
copolymer shifted to 18.58 min. There was just one narrow
peak for the random copolymer, and the TPGS peak could
not be detected. The polydispersity of the copolymer
molecular weight was narrow, which was around 1.30.
The number-averaged molecular weight calculated from
the GPC chromatograph was 21,944. It appeared that the
molecular weight measured from GPC and NMR could
conﬁrm each other.
Thermogravimetric analysis (TGA) was performed on
the synthesized PLGA-TPGS random copolymer in order
to investigate its thermal property. Figure 5 shows the
typical thermal degradation proﬁles for TPGS monomer
and PLGA-TPGS random copolymer. It was observed that
the thermal degradation proﬁle of PLGA-TPGS random
copolymer showed two regions of weight loss, which were
different from a single mass loss for the TPGS monomer.
Each turning point marked the combustion of a new
component in the random copolymers. The 200–315C and
315–450C combustion zones were attributed to PLGA and
TPGS part of copolymer, respectively. The TPGS com-
position of the PLGA-TPGS copolymer calculated from
TGA was 10.71%, which could match very well with NMR
result and also conﬁrmed the synthesis of PLGA-TPGS
random copolymer. Thus, TGA was a convenient means
for evaluating the mass ratios of the PLGA-TPGS random
copolymer. Liggins et al. [22] also found that PLA-MPEG
Fig. 2 FTIR spectra of PLGA-TPGS random copolymer and TPGS
Fig. 3 Typical
1H-NMR spectra of PLGA-TPGS random copolymer
and TPGS
Fig. 4 Typical GPC chromatograms of PLGA-TPGS random copoly-
mer and TPGS
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123copolymers demonstrated a biphasic thermal degradation
proﬁle, and TGA was applicable as composition calcula-
tion for PEGylated copolymers.
Characterization of Drug-Loaded Nanoparticles
Size, Size Distribution and Drug Encapsulation Efﬁciency
The size and size distribution of the docetaxel-loaded
PLGA-TPGS nanoparticles prepared in this research are
shown in Table 1. The particle size was found from
207.15 nm to 244.71 with size distribution of less than 0.4
polydispersity for samples without extra TPGS. Addition
of TPGS in the process as emulsiﬁer slightly increased the
particle size, which agreed with the previous report [6].
The mean particle size was found around 265.43 nm with
size distribution of 0.36 polydispersity for samples with the
addition of 0.03% TPGS and around 290.25 nm with size
distribution of 0.48 polydispersity for samples with the
addition of 0.06% TPGS. The coating effect of TPGS on
the particle surface and the aggregation of the formed
nanoparticles because of extra TPGS may account for the
increases in nanoparticle size.
Table 1 also shows the drug loading and surfactant
effects on size and size distribution and the drug EE. The
PLGA-TPGS nanoparticles prepared without the addition
of emulsiﬁer can result in a relative lower EE, which was
found to be 48.35% for 10% drug loading and 58.87% for
2.5% drug loading. For the high drug loading of 10%,
however, the EE of the docetaxel-loaded PLGA-TPGS
nanoparticles can be improved by the addition of TPGS in
the process as emulsiﬁer. The drug EE increased signiﬁ-
cantly to near 100% for 10% drug loading when 0.03%
TPGS was added as emulsiﬁer and to 85.85% when 0.06%
TPGS was added. Thus, too little emulsiﬁer would not be
enough to cover the interface and too much emulsiﬁer
would cause nanoparticle aggregation [23]. It can be seen
from Table 1 that 0.03% TPGS used as an emulsiﬁer did
improve the EE of the PLGA-TPGS nanoparticles from
48.35 to 99.31% for a high drug loading of 10%.
Surface Charge
Zeta potential determines the particle stability in disper-
sion. High absolute value of the zeta potential suggests
high surface charge of the nanoparticles, which leads to
strong repellent interactions among the nanoparticles in
dispersion and thus high stability [19]. As shown in
Table 1, the absolute value of zeta potential for docetaxel-
loaded PLGA-TPGS nanoparticles was found to be about
18.03 mV, which was slightly lower than that of nano-
particles fabricated from PLGA, indicating a slightly lower
stability for docetaxel-loaded PLGA-TPGS nanoparticles.
The negative surface charge of PLGA-TPGS nanoparticles
may be attributed to the presence of ionized carboxyl
groups of PLA and PGA segments on the nanoparticles
surface.
Surface Morphology
Figure 6 shows the FESEM images of the docetaxel-loaded
PLGA and PLGA-TPGS nanoparticles. Both PLGA and
PLGA-TPGS nanoparticles were spherical in shape and
appear smooth within the FESEM resolution level. Their
Fig. 5 Thermogravimetric proﬁles of PLGA-TPGS random copoly-
mer and TPGS
Table 1 Characterization of drug-loaded nanoparticles
Polymer Drug loading (%) Surfactant Size (nm) PDI ZP (mV) EE (%)
PLGA-TPGS 2.5 No 207.15 ± 8. 46 0.321 ± 0.03 58.87 ± 3.25
PLGA-TPGS 5 No 223.92 ± 6.27 0.372 ± 0.04 52.58 ± 2.94
PLGA-TPGS 10 No 244.71 ± 6.65 0.415 ± 0.02 -24.09 ± 1.45 48.35 ± 5.73
PLGA-TPGS 10 0.03% TPGS 265.43 ± 6.52 0.364 ± 0.03 -18.03 ± 1.89 99.31 ± 0.56
PLGA-TPGS 10 0.06% TPGS 290.25 ± 7.64 0.485 ± 0.01 -15.22 ± 2.12 85.85 ± 3.14
PLGA 10 0.03% TPGS 233.83 ± 9.62 0.293 ± 0.03 -32.10 ± 0.65 75.63 ± 3.42
* PDI Polydispersity Index, EE Drug encapsulation efﬁciency, n = 3
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123size was observed to be around 250 nm, which further
conﬁrmed the results of particle size determined by DLS.
Differential Scanning Calorimetry (DSC)
The physical state of docetaxel in the nanoparticles that
could inﬂuence the in vitro and in vivo release of the drug
from the systems was investigated by differential scanning
calorimetry (DSC). Figure 7 shows the DSC thermograms
of pure docetaxel powder, docetaxel-loaded PLGA-TPGS
nanoparticles and docetaxel-loaded PLGA nanoparticles.
The melting endothermic peak of pure docetaxel appeared
at 173C. However, no melting peak was detected for both
nanoparticle formulations. Thus, it can be concluded that
docetaxel inside the nanoparticles was either in an amor-
phous, disordered crystalline phase or in the solid solution
state.
In Vitro Drug Release
As shown by Fig. 8, the in vitro drug release proﬁles of the
docetaxel-loaded PLGA-TPGS nanoparticles and PLGA
nanoparticles showed biphasic release pattern with an ini-
tial burst followed by a sustained release. The drug release
from the PLGA-TPGS nanoparticles was found to be 22.83
and 58.61% of the encapsulated drug in the ﬁrst three days
and after 28 days, respectively, which was much faster
than the docetaxel-loaded PLGA nanoparticles in the same
periods. The faster drug release of the PLGA-TPGS
nanoparticles may be caused by the lower molecular
weight and the higher hydrophilicity of PLGA-TPGS ran-
dom copolymer in comparison with the PLGA nanoparti-
cles. This is also another advantage of the PLGA-TPGS
nanoparticles versus the traditional PLGA nanoparticles,
which were found to release the drug too slowly to meet the
therapeutic needs.
Cellular Uptake of Coumarin-6–Loaded PLGA-TPGS
Nanoparticles
Confocal laser scanning microscopy (CLSM) images
(Fig. 9) showed that the ﬂuorescence of the coumarin-
6–loaded PLGA-TPGS nanoparticles (green) was closely
located around the nuclei (blue, stained by DAPI), which
indicated that the coumarin-6–loaded PLGA-TPGS nano-
particles had been internalized into the cells.
Fig. 6 FESEM images of
docetaxel-loaded nanoparticles
with 0.03% TPGS as emulsiﬁer
and 10% drug loading.
a, Docetaxel-loaded PLGA
nanoparticles; b, docetaxel-
loaded PLGA-TPGS
nanoparticles
Fig. 7 DSC thermograms of pure docetaxel, docetaxel-loaded PLGA-
TPGS nanoparticles and docetaxel-loaded PLGA nanoparticles
Fig. 8 In vitro drug release proﬁles of docetaxel-loaded PLGA and
PLGA-TPGS nanoparticles
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The in vitro cytotoxicity of drug-free PLGA-TPGS nano-
particles and docetaxel-loaded PLGA-TPGS nanoparticles
in HeLa cell line was assessed by the MTT assay. The
range of concentrations of docetaxel (0.25–25 lg/ml)
corresponds to plasma levels of the drug achievable in
humans [24]. From Fig. 10, we can draw some general
conclusions: (1) no obvious cytotoxicity was observed for
the drug-free nanoparticles at various nanoparticle con-
centrations. The synthesized PLGA-TPGS copolymer was
considered biocompatible since the drug-free PLGA-TPGS
nanoparticles show little decrease in cellular viability for
Hela cells; (2) the docetaxel-loaded PLGA-TPGS nano-
particles showed signiﬁcant cytotoxicity against Hela cells.
Hela cell viability decreased from 91.37% for drug-loaded
PLGA-TPGS nanoparticles containing 0.25 lg/ml doce-
taxel to 82.65% for drug-loaded PLGA-TPGS nanoparti-
cles containing 25 lg/ml docetaxel after 24-h cell culture
(8.62% more effective in vitro therapeutic effect, p\
0.05). After 48-h cell culture, the cell viability decreased
from 65% for drug-loaded PLGA-TPGS nanoparticles
containing 0.25 lg/ml docetaxel to 47.21% for drug-loaded
PLGA-TPGS nanoparticles containing 25 lg/ml docetaxel
(17.79% more effective in vitro therapeutic effect, p\
0.05). Other concentrations of drug-loaded PLGA-TPGS
nanoparticles showed similar in vitro therapeutic effects;
(3) the cellular viability decreased with the incubation
period in all cases. For example, Hela cell viability
decreased from 88% for drug-loaded PLGA-TPGS nano-
particles containing 2.5 lg/ml docetaxel after 24-h cell
culture to 60% after 48-h cell culture (28% more effective
in vitro therapeutic effect, p\0.01) and achieved 22.98%
cell viability after 72-h cell culture (38.02% more effective
in vitro therapeutic effect than that of 48-h treatment,
p\0.01). With the increase in docetaxel concentration,
more effective in vitro therapeutic effects could be
observed. The strongest in vitro therapeutic effect could be
found in 25 lg/ml docetaxel concentration, which achieved
19.61% cell viability after 72-h cell culture, because the
nanoparticles released the most amounts of drugs and the
degradation of PLGA-TPGS random copolymer may
release the most amounts of TPGS components that have
synergistic anticancer activity in the presence of anticancer
agent [14–16] after 72-h incubation.
Conclusion
For the ﬁrst time, the poly(lactide-co-glycolide)-d-a-toc-
opheryl polyethylene glycol 1000 succinate (PLGA-TPGS)
random copolymers were successfully synthesized as
nanoparticle carrier of small molecular anticancer drugs
with docetaxel as a model drug. The docetaxel-loaded
Fig. 9 Confocal laser scanning microscopy (CLSM) images of HeLa
cells after 4-h incubation with coumarin-6–loaded PLGA-TPGS
nanoparticles at 37.0C. The cells were stained by DAPI (blue) and
the coumarin-6–loaded nanoparticles are green. The cellular uptake
was visualized by overlaying images obtained by EGFP ﬁlter and
DAPI ﬁlter: left image from EGFP channel (a); center image
from DAPI channel (b); right image from combined EGFP channel
and DAPI channel (c)
Fig. 10 Cytotoxicity of Hela cells cultured with drug-free nanopar-
ticles and docetaxel-loaded PLGA-TPGS nanoparticles containing
0.25, 2.5, 12.5 or 25 lg/ml docetaxel concentrations after 24-, 48- and
72-h cell culture. (n = 3)
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123PLGA-TPGS nanoparticles were prepared by a modiﬁed
solvent extraction/evaporation method. The size of such
nanoparticles was found to be around 250 nm. The doce-
taxel-loaded PLGA-TPGS nanoparticles could achieve
much faster drug release in comparison with PLGA
nanoparticles. In vitro cellular uptakes of such nanoparti-
cles were investigated by CLSM, demonstrating the ﬂuo-
rescence PLGA-TPGS nanoparticles could be internalized
by human cervix carcinoma cells (HeLa). The results
showed that PLGA-TPGS–based nanoparticles were bio-
compatible, and the docetaxel-loaded PLGA-TPGS nano-
particles had signiﬁcant cytotoxicity against Hela cells.
The cytotoxicity against HeLa cells for PLGA-TPGS
nanoparticles was in time- and concentration-dependent
manner. In conclusion, PLGA-TPGS random copolymer
could be acted as a novel and potential biocompatible
polymeric matrix material applicable to nanoparticle-based
drug delivery system for cancer chemotherapy.
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